Eradication rates in per-protocol analysis in the first-line treatment according to antibiotic resistance and clinical factors
| Variables | LAL | p Value | CAL | p Value |
| Levofloxacin | 0.018 | 0.479 | ||
| Susceptible | 103/122 (84.4%) | 113/128 (79.1%) | ||
| Resistant | 5/10 (50%) | 4/5 (80%) | ||
| Clarithromycin | 0.426 | 0.002 | ||
| Susceptible | 93/113 (82.3%) | 107/118 (90.7%) | ||
| Resistant | 8/11 (72.7%) | 4/9 (44.4%) | ||
| Amoxicillin | 0.001 | 0.321 | ||
| Susceptible | 107/127 (84.3%) | 115/130 (88.5%) | ||
| Resistant | 1/4 (25%) | 2/3 (66.7%) | ||
| Gender | 0.648 | 0.206 | ||
| Men | 68/87 (78.2%) | 79/87 (90.8%) | ||
| Women | 93/114 (81.6%) | 101/119 (84.9%) | ||
| Centre | 0.671 | 0.277 | ||
| NTUH | 128/161 (79.5%) | 143/166 (86.1%) | ||
| E-DA | 33/40 (82.5%) | 37/40 (92.5%) | ||
| Diagnosis | 0.575 | 0.924 | ||
| Peptic ulcer | 60/73 (82.2%) | 71/81 (87.7%) | ||
| Without peptic ulcer | 101/128 (78.9%) | 109/125 (87.2%) |
χ2 test and Fisher exact test were used as appropriate.
CAL, clarithromycin, amoxicillin and lansoprazole; E-DA, E-DA hospital; LAL, levofloxacin, amoxicillin and lansoprazole; NTUH, National Taiwan University Hospital.